“I have always been attracted to innovative products. I know that this means that you need to take a chance sometimes, but having worked within the biotechnology and pharmaceutical industries, I am used to risk assessment. The risk with the Certified Learning Provider program was not really that great, particularly when you compare the cost to traditional academic programs or other professional programs and I liked the fact that you could study each part of the program and pay for it over a sustainable period of time. I also liked the fact that clients were engaged before I had to develop the program. This provided me with the required peace of mind and motivation to do the work and took pressure off during the development phase. I also scaled down my own client base and started working as an Associate with Appleton Greene while studying, which provided both income and insight into how things worked. When you consider how much it would cost financially to do this on your own, without any support or assistance, then the cost of the CLP program is insignificant by comparison. I was a banker in a previous life, so I always calculate and compare the return on investment with what I could achieve in interest. I would be lucky to receive 5% annual interest at a bank at the moment, my return on investment with Appleton Greene has consistently been over 1,000%, taking into consideration all of my fixed and variable costs. This investment has been well worthwhile”

A quotation taken from a Learning Provider reference within the Biotechnology industry.

  • Actelion
  • Alexion Pharmaceuticals
  • Alkermes
  • Amgen
  • Ariad Pharmaceuticals
  • Biogen Idec
  • BioMarin Pharmaceutical
  • Celgene
  • CSL
  • Cubist Pharmaceuticals
  • DiaSorin
  • Reddy’s Laboratories
  • Élan
  • Gilead Sciences
  • Ipsen Group
  • Merck KGaA
  • Novo Nordisk
  • Onyx Pharmaceuticals
  • Regeneron
  • Seattle Genetics
  • Shire plc
  • Teva Pharmaceutical Industries
  • UCB Company
  • United Therapeutics
  • Vertex Pharmaceuticals

Biotechnology is the use of living systems and organisms to develop or make useful products, or any technological application that uses biological systems, living organisms or derivatives thereof, to make or modify products or processes for specific use. For thousands of years, humankind has used biotechnology in agriculture, food production, and medicine. Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non food (industrial) uses of crops and other products (e.g. biodegradable plastics, vegetable oil, bio-fuels), and environmental uses. The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research. The global biotechnology market has total revenues of $304.0bn, representing a compound annual growth rate (CAGR) of 9.6%. The medical/healthcare segment is the market’s most lucrative, with total revenues of $182.5bn, equivalent to 60.0% of the market’s overall value. The performance of the market is forecast to decelerate, with an anticipated CAGR of 9%, which is expected to drive the market to a value of $468.2bn.


“Appleton Greene appears to attract very creative and imaginative people and then provides them with a structured approach to product development and implementation. This must be a very rewarding experience for it’s trainers and consultants. Anything that helps our employees to tap into their creative side is always welcome and it certainly helps sometimes if this is initiated using an independent external perspective.”

A quotation taken from a client reference within the Biotechnology industry.